Abiotic formation of O2 and O3 in high-CO2 terrestrial atmospheres

Previous research has indicated that high amounts of ozone (O3) and oxygen (O2) may be produced abiotically in atmospheres with high concentrations of CO2. The abiotic production of these two gases, which are also characteristic of photosynthetic life processes, could pose a potential "false-positive" for remote-sensing detection of life on planets around other stars.We show here that such false positives are unlikely on any planet that possesses abundant liquid water, as rainout of oxidized species onto a reduced planetary surface should ensure that atmospheric H2 concentrations remain relatively high, and that O2 and O3 remain low. Our aim is to determine the amount of O3 and O2 formed in a high CO2 atmosphere for a habitable planet without life. We use a photochemical model that considers hydrogen (H2) escape and a detailed hydrogen balance to calculate the O2 and O3 formed on planets with 0.2 of CO2 around the Sun, and 0.02, 0.2 and 2 bars of CO2 around a young Sun-like star with higher UV radiation. The concentrations obtained by the photochemical model were used as input in a radiative transfer model that calculated the spectra of the modeled planets. The O3 and O2 concentrations in the simulated planets are extremely small, and unlikely to produce a detectable signature in the spectra of those planets. We conclude that with a balanced hydrogen budget, and for planets with an active hydrological cycle, abiotic formation of O2 and O3 is unlikely to create a possible false positive for life detection in either the visible/near-infrared or mid-infrared wavelength regimes.Comment: 27 pages, 15 figures, Astronomy & Astrophysics accepte

Resuscitation with pre-hospital blood products in adults with trauma-related haemorrhagic shock:the RePHILL RCT

Background: The treatment of traumatic haemorrhagic shock has been transformed through better haemorrhage control, use of tranexamic acid and use of blood products. The improved survival seen from these strategies has stimulated an interest in pre-hospital transfusion.Objectives: To determine if the clinical effectiveness of resuscitation with red blood cells and lyophilised plasma was superior to 0.9% saline for improving tissue perfusion and reducing mortality in adults with haemorrhagic shock following major trauma.Design: A multi-centre, allocation concealed, open-label, parallel group, randomised controlled trial (with internal pilot).Setting: The trial was conducted in four civilian pre-hospital critical care services who operated within the National Health Service (NHS) England Major Trauma Networks.Participants: Adults (aged ≥16 years) who had sustained traumatic injuries, were attended by a pre-hospital emergency medical team and were hypotensive (systolic blood pressure &lt;90 mmHg or absence of radial pulse) as a consequence of traumatic haemorrhage were eligible for inclusion. The exclusion criteria were known or apparently &lt;16 years, blood administered on scene prior to the arrival of the RePHILL team, traumatic cardiac arrest where (1) the arrest occurred prior to arrival of the team and/or (2) the primary cause is not hypovolaemia, refusal of blood product administration, known Jehovah’s Witness, pregnancy, isolated head injury without evidence of external haemorrhage, prisoners in the custody of HM Prison and Probation Service.Interventions: Participants were randomised to receive up to either two units each of red blood cells and lyophilised plasma or up to 1 L 0.9% saline. Treatment was administered through the intravenous or intraosseous route.Main outcome measures: The primary outcome was a composite of episode mortality and/or impaired lactate clearance. The secondary outcomes included the individual components of the primary outcome.Results: From 6 December 2016 to 2 January 2021, pre-hospital medical teams randomised 432 participants to red blood cell/lyophilised plasma (n = 209) or 0.9% saline (n = 223) out of a target sample size of 490. Most participants were white (62%), males (82%), median age 38 (interquartile range 26 to 58), involved in a road traffic collision (62%) with severe injuries (median injury severity score 36, interquartile range 25 to 50). Prior to randomisation participants had received on average 430 ml crystalloid fluids and tranexamic acid (90%). The primary outcome occurred in 128/199 (64.3%) of participants randomised to red blood cell/lyophilised plasma and 136/210 (64.8%) randomised to 0.9% saline [adjusted risk difference –0.025% (95% confidence interval –9.0% to 9.0%), p = 0.996]. The event rates for the individual components of the primary outcome, episode mortality and lactate clearance were not statistically different between groups [adjusted average differences −3% (−12% to 7%); p = 0.57 and −5% (−14% to 5%), p = 0.33, respectively].Limitations: Recruitment stopped prematurely due to disruption caused by the COVID-19 pandemic.Future work: Identify the characteristics of patients who may benefit from pre-hospital blood products and whether alternative transfusion regimens are superior to standard care.Conclusions: The trial did not demonstrate that pre-hospital red blood cell/lyophilised plasma resuscitation was superior to 0.9% saline for trauma-related haemorrhagic shock.Trial registration: This trial is registered as ISRCTN62326938.Funding: This award was funded by the National Institute for Health and Care Research (NIHR) Efficacy and Mechanism Evaluation Programme (NIHR award ref: 14/152/14) and is published in full in Efficacy and Mechanism Evaluation; Vol. 11, No. 2. See the NIHR Funding and Awards website for further award information.<br/

The effect of atmospheric acid processing on the global deposition of bioavailable phosphorus from dust

The role of dust as a source of bioavailable phosphorus (Bio-P) is quantified using a new parameterization for apatite dissolution in combination with global soil data maps and a global aerosol transport model. Mineral dust provides 31.2 Gg-P yr-1 of Bio-P to the oceans, with 14.3 Gg-P yr-1 from labile P present in the dust, and an aditional 16.9 Gg-P yr from acid dissolution of apatite in the atmosphere, representing an increase of 120%. The North Atlantic, north west Pacific, and Mediterranean Sea are identified as important sites of Bio-P deposition from mineral dust. The acid dissolution process increases the fraction of total-P that is bioavailable from ~10% globally from the labile pool to 23% in the Atlantic Ocean, 45% in the Pacific Ocean, and 21% in the Indian Ocean, with an ocean global mean value of 22%. Strong seasonal variations, especially in the North Pacific, northwest Atlantic, and Indian Ocean, are driven by large-scale meteorology and pollution sources from industrial and biomass-burning regions. Globally constant values of total-P content and bioavailable fraction used previously do not capture the simulated variability. We find particular sensitivity to the representation of particle-to-particle variability of apatite, which supplies Bio-P through acid-dissolution, and calcium carbonate, which helps to buffer the dissolution process. A modest 10% external mixing results in an increase of Bio-P deposition by 18%. The total Bio-P calculated here (31.2 Gg-P yr-1) represents a minimum compared to previous estimates due to the relatively low total-P in the global soil map used

Circulating microRNAs in sera correlate with soluble biomarkers of immune activation but do not predict mortality in ART treated individuals with HIV-1 infection: A case control study

Introduction: The use of anti-retroviral therapy (ART) has dramatically reduced HIV-1 associated morbidity and mortality. However, HIV-1 infected individuals have increased rates of morbidity and mortality compared to the non-HIV-1 infected population and this appears to be related to end-organ diseases collectively referred to as Serious Non-AIDS Events (SNAEs). Circulating miRNAs are reported as promising biomarkers for a number of human disease conditions including those that constitute SNAEs. Our study sought to investigate the potential of selected miRNAs in predicting mortality in HIV-1 infected ART treated individuals. Materials and Methods: A set of miRNAs was chosen based on published associations with human disease conditions that constitute SNAEs. This case: control study compared 126 cases (individuals who died whilst on therapy), and 247 matched controls (individuals who remained alive). Cases and controls were ART treated participants of two pivotal HIV-1 trials. The relative abundance of each miRNA in serum was measured, by RTqPCR. Associations with mortality (all-cause, cardiovascular and malignancy) were assessed by logistic regression analysis. Correlations between miRNAs and CD4+ T cell count, hs-CRP, IL-6 and D-dimer were also assessed. Results: None of the selected miRNAs was associated with all-cause, cardiovascular or malignancy mortality. The levels of three miRNAs (miRs -21, -122 and -200a) correlated with IL-6 while miR-21 also correlated with D-dimer. Additionally, the abundance of miRs -31, -150 and -223, correlated with baseline CD4+ T cell count while the same three miRNAs plus miR- 145 correlated with nadir CD4+ T cell count. Discussion: No associations with mortality were found with any circulating miRNA studied. These results cast doubt onto the effectiveness of circulating miRNA as early predictors of mortality or the major underlying diseases that contribute to mortality in participants treated for HIV-1 infection

O3oxidation of SO2in sea-salt aerosol water: Size distribution of non-sea-salt sulfate during the First Aerosol Characterization Experiment (ACE 1)

Non sea-salt sulfate (NSS) of 2.2-2.3 nmol m(-3) total magnitude in aerosols observed during the First Aerosol Characterization Experiment (ACE-1) at Cape Grim, Tasmania, was trimodally distributed with similar to 1 nmol NSS m(-3) in > 0.7 mu m ambient diameter (diam) coarse seasalt mode aerosols; despite this low NSS concentration, [H2SO4(g)] was so low that 0.7 mu m diam aerosols. The mechanism of O-3 oxidation of SO2 in sea-salt aerosol water (SSAW) is assessed for its capability to explain this coarse aerosol NSS. Limitation of this mechanism's NSS contribution is largely due to SSAW's buffering capacity since its reaction rate is reduced by 2 orders of magnitude at pH 6 versus the pH greater than or equal to 8 of unreacted SSAW. However, the buffering capacity of sea-salt aerosols may have been significantly enhanced over that of bulk seawater alkalinity. This appears to be due to carbonate resulting from small fragments of biogenic CaCO3 in the ocean's surface microlayer. Given the observed nonsoil calcium excess over that in bulk seawater, the estimated actual buffering capacity of sea-salt aerosols observed during ACE 1 was 50%, or more, enhanced over that due to bulk seawater alkalinity. Considering this enhanced buffering capacity, O-3 oxidation of SO2 in SSAW can produce sufficient NSS to explain 70-90% of the similar to 1 nmol m(-3) found in > 0.7 mu m diam coarse sea-salt aerosols with cloud processing and further oxidation of SO2 in SSAW (i.e., pH < 6) by other sea-salt conversion mechanisms contributing the remainder. The amount of NSS produced by sea-salt conversion mechanisms during the ACE 1 remote Southern Ocean experiment vied with homogeneous and cloud processing in their contribution to the total observed NSS of 2.2-2.3 nmol m(-3)

Development and Validation of a Risk Score for Chronic Kidney Disease in HIV Infection Using Prospective Cohort Data from the D:A:D Study

Ristola M. on työryhmien DAD Study Grp ; Royal Free Hosp Clin Cohort ; INSIGHT Study Grp ; SMART Study Grp ; ESPRIT Study Grp jäsen.Background Chronic kidney disease (CKD) is a major health issue for HIV-positive individuals, associated with increased morbidity and mortality. Development and implementation of a risk score model for CKD would allow comparison of the risks and benefits of adding potentially nephrotoxic antiretrovirals to a treatment regimen and would identify those at greatest risk of CKD. The aims of this study were to develop a simple, externally validated, and widely applicable long-term risk score model for CKD in HIV-positive individuals that can guide decision making in clinical practice. Methods and Findings A total of 17,954 HIV-positive individuals from the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) study with >= 3 estimated glomerular filtration rate (eGFR) values after 1 January 2004 were included. Baseline was defined as the first eGFR > 60 ml/min/1.73 m2 after 1 January 2004; individuals with exposure to tenofovir, atazanavir, atazanavir/ritonavir, lopinavir/ritonavir, other boosted protease inhibitors before baseline were excluded. CKD was defined as confirmed (>3 mo apart) eGFR In the D:A:D study, 641 individuals developed CKD during 103,185 person-years of follow-up (PYFU; incidence 6.2/1,000 PYFU, 95% CI 5.7-6.7; median follow-up 6.1 y, range 0.3-9.1 y). Older age, intravenous drug use, hepatitis C coinfection, lower baseline eGFR, female gender, lower CD4 count nadir, hypertension, diabetes, and cardiovascular disease (CVD) predicted CKD. The adjusted incidence rate ratios of these nine categorical variables were scaled and summed to create the risk score. The median risk score at baseline was -2 (interquartile range -4 to 2). There was a 1: 393 chance of developing CKD in the next 5 y in the low risk group (risk score = 5, 505 events), respectively. Number needed to harm (NNTH) at 5 y when starting unboosted atazanavir or lopinavir/ritonavir among those with a low risk score was 1,702 (95% CI 1,166-3,367); NNTH was 202 (95% CI 159-278) and 21 (95% CI 19-23), respectively, for those with a medium and high risk score. NNTH was 739 (95% CI 506-1462), 88 (95% CI 69-121), and 9 (95% CI 8-10) for those with a low, medium, and high risk score, respectively, starting tenofovir, atazanavir/ritonavir, or another boosted protease inhibitor. The Royal Free Hospital Clinic Cohort included 2,548 individuals, of whom 94 individuals developed CKD (3.7%) during 18,376 PYFU (median follow-up 7.4 y, range 0.3-12.7 y). Of 2,013 individuals included from the SMART/ESPRIT control arms, 32 individuals developed CKD (1.6%) during 8,452 PYFU (median follow-up 4.1 y, range 0.6-8.1 y). External validation showed that the risk score predicted well in these cohorts. Limitations of this study included limited data on race and no information on proteinuria. Conclusions Both traditional and HIV-related risk factors were predictive of CKD. These factors were used to develop a risk score for CKD in HIV infection, externally validated, that has direct clinical relevance for patients and clinicians to weigh the benefits of certain antiretrovirals against the risk of CKD and to identify those at greatest risk of CKD.Peer reviewe